PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34273250-0	2021	Prediction of the drug-drug interaction potential of the alpha-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib.	erdafitinib	129-140	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	95-101	
34273250-2	2021	Erdafitinib binds preferentially to alpha1-acid glycoprotein (AGP), and is primarily metabolized by cytochrome P450 (CYP) 2C9 and 3A4.	erdafitinib	0-11	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	100-125	
34273250-3	2021	This article describes a physiologically based pharmacokinetic (PBPK) model for erdafitinib to assess the drug-drug interaction (DDI) potential of CYP3A4 and CYP2C9 inhibitors, and CYP3A4/CYP2C9 inducers on erdafitinib PK in cancer patients exhibiting higher AGP levels and in population with different CYP2C9 genotypes.	erdafitinib	80-91	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	158-164	
34273250-3	2021	This article describes a physiologically based pharmacokinetic (PBPK) model for erdafitinib to assess the drug-drug interaction (DDI) potential of CYP3A4 and CYP2C9 inhibitors, and CYP3A4/CYP2C9 inducers on erdafitinib PK in cancer patients exhibiting higher AGP levels and in population with different CYP2C9 genotypes.	erdafitinib	80-91	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	188-194	
34273250-3	2021	This article describes a physiologically based pharmacokinetic (PBPK) model for erdafitinib to assess the drug-drug interaction (DDI) potential of CYP3A4 and CYP2C9 inhibitors, and CYP3A4/CYP2C9 inducers on erdafitinib PK in cancer patients exhibiting higher AGP levels and in population with different CYP2C9 genotypes.	erdafitinib	80-91	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	303-309	
34273250-3	2021	This article describes a physiologically based pharmacokinetic (PBPK) model for erdafitinib to assess the drug-drug interaction (DDI) potential of CYP3A4 and CYP2C9 inhibitors, and CYP3A4/CYP2C9 inducers on erdafitinib PK in cancer patients exhibiting higher AGP levels and in population with different CYP2C9 genotypes.	erdafitinib	207-218	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	188-194	
34273250-6	2021	Erdafitinib clearance in the PBPK model consisted of multiple pathways (CYP2C9/3A4, renal, intestinal; additional hepatic clearance), making the compound less susceptible to DDIs.	erdafitinib	0-11	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	72-82	
34273250-7	2021	In poor metabolizing CYP2C9 populations carrying the CYP2C9*3/*3 genotype, simulations shown clinically relevant increase in erdafitinib plasma concentrations.	erdafitinib	125-136	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	21-27	
34273250-7	2021	In poor metabolizing CYP2C9 populations carrying the CYP2C9*3/*3 genotype, simulations shown clinically relevant increase in erdafitinib plasma concentrations.	erdafitinib	125-136	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	53-59	
31673875-1	2020	BACKGROUND AND OBJECTIVES: Erdafitinib, an oral selective pan-fibroblast growth factor receptor (FGFR) kinase inhibitor, is primarily metabolized by cytochrome P450 (CYP) 2C9 and 3A4.	erdafitinib	27-38	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	149-174	
31673875-2	2020	The aim of this phase 1 study was to assess the pharmacokinetics and safety of erdafitinib in healthy participants when coadministered with fluconazole (moderate CYP2C9 and CYP3A inhibitor), and itraconazole (a strong CYP3A4 and P-glycoprotein inhibitor).	erdafitinib	79-90	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	162-168	
31673875-12	2020	CONCLUSION: Coadministration of fluconazole or itraconazole or other moderate/strong CYP2C9 or CYP3A4 inhibitors may increase exposure to erdafitinib in healthy adults and thus may warrant erdafitinib dose reduction or use of alternative concomitant medications with no or minimal CYP2C9 or CYP3A4 inhibition potential.	erdafitinib	138-149	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	85-91	
31673875-12	2020	CONCLUSION: Coadministration of fluconazole or itraconazole or other moderate/strong CYP2C9 or CYP3A4 inhibitors may increase exposure to erdafitinib in healthy adults and thus may warrant erdafitinib dose reduction or use of alternative concomitant medications with no or minimal CYP2C9 or CYP3A4 inhibition potential.	erdafitinib	138-149	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	281-287	
31673875-12	2020	CONCLUSION: Coadministration of fluconazole or itraconazole or other moderate/strong CYP2C9 or CYP3A4 inhibitors may increase exposure to erdafitinib in healthy adults and thus may warrant erdafitinib dose reduction or use of alternative concomitant medications with no or minimal CYP2C9 or CYP3A4 inhibition potential.	erdafitinib	189-200	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	85-91